Cambridge, United States
Stipple Bio, founded in 2022 by cancer biology experts Aaron Ring and Aashish Manglik, is positioning itself at the forefront of oncology therapeutics. This biotechnology company is leveraging its proprietary Pointillist Platform to enhance precision in cancer therapy. By targeting tumor-specific cell surface epitopes with greater accuracy, Stipple Bio aims to improve therapeutic indices and explore targets that are challenging with conventional methods.
The company's flagship candidate, the ADC STP-100, exemplifies this novel epitope-targeting strategy. Backed by investments co-led by RA Capital, a16z Bio+Health, and Nextech Invest, with support from Emerson Collective Investments, GV, LoLa Capital Partners, and GordonMD Global Investments, Stipple Bio is poised to significantly impact the oncology drug discovery landscape. Their mission is to develop next-generation therapeutics that could dramatically improve the lives of cancer patients worldwide.
